The chemical formula of pemetinib/pemetinib

Pemigatinib/Pemigatinib is a kinase inhibitor with the chemical name 3-(2,6-difluoro-3,5-di Methoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3’,2’:5,6]pyrido[4,3-d]pyrimidin-2-one. The molecular formula of pemetinib is C24H27F2N5O4, and its molecular weight is 487.5g/mole. Pemetinib is a white to off-white solid, non-hygroscopic. Pemetinib tablets are uncoated oral tablets. Tablets contain 4.5 mg, 9 mg, or 13.5 mg of the active ingredient pemigatinib.

Pemetinib is used in adults to treat cholangiocarcinoma that has spread to other parts of the body (metastatic) or cannot be removed with surgery. Pemetinib is usually given after the cancer has been treated with another drug. Pemetinib can only be used if a patient's cancer has a specific genetic marker (an abnormal"FGFR2" gene). Doctors will test for the presence of this gene. The U.S. Food and Drug Administration (FDA) approved pemetinib on an “accelerated” basis. In clinical studies, some people responded to pemetinib, but further study is needed. Pemetinib may also be used for purposes not listed in this Medication Guide.

In animal studies, pemetinib caused fetal injury and embryonic-fetal death in pregnant rats. The FDA recommends that nursing women avoid breastfeeding while receiving pemetinib. At the 13.5 mg clinical dose, solid bone and chondrodysplasia were seen in multiple bones in rats and non-human primates, and pemetinib exposure was lower than human exposure.